UFPT Earnings

UFPT reported its FY2025Q4 earnings on 2026-02-24, showcasing a revenue of against an estimate of 155.38M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 2.26 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following UFPT's FY2025Q4 earnings announcement on 2026-02-24, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, UFPT's stock price tends to shift by an average of -1.84% in the 10 days leading up to earnings and +1.28% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate UFPT’s annual revenue to reach 149.07M, while the EPS is projected at 2.07. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.15% and EPS estimates Revise Upward by 0.61% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between UFPT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.15%, while EPS estimates moved Revise Upward by 0.61% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, UFPT's stock price typically moves by -1.84% in the 10 days before its earnings and +1.28% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 2.07 and revenue of 149.07M.

The earnings call reflects a positive sentiment with key highlights: a 5.1% increase in robotic surgery revenue, strong demand in interventional orthopedics, and successful acquisitions. Despite AJR's labor issues, the company maintains a stable operating margin and continues debt reduction. The Q&A section reveals optimism about future contracts and growth, particularly with Intuitive. Although AJR inefficiencies impact margins, improvements are anticipated. The market cap suggests moderate sensitivity to these developments, leading to a positive stock price prediction.